Danaher Corporation (NYSE:DHR) Stock Has Consensus Target Price of $235.23 According to Brokerages

Shares of Danaher Corporation (NYSE:DHR) have been assigned an average rating of “Moderate Buy” from the twenty-three analysts that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $235.41.

A number of brokerages have recently issued reports on DHR. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Barclays lifted their target price on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Evercore reiterated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. TD Cowen upped their target price on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada increased their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th.

Danaher Stock Performance

Shares of NYSE DHR opened at $224.65 on Friday. The firm has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. Danaher has a one year low of $160.93 and a one year high of $242.80. The business has a fifty day simple moving average of $212.92 and a 200 day simple moving average of $195.39. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the company earned $0.77 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. Sell-side analysts expect that Danaher will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Hedge Funds Weigh In On Danaher

Hedge funds have recently modified their holdings of the stock. Veery Capital LLC increased its stake in shares of Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares during the period. Studio Investment Management LLC raised its position in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after acquiring an additional 51 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares during the period. JDH Wealth Management LLC lifted its stake in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock valued at $240,000 after acquiring an additional 55 shares during the period. Finally, OLD Second National Bank of Aurora lifted its stake in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after acquiring an additional 57 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.